• Philips Extends Partnership with Cortechs.ai, Rapid Diagnostic Sepsis Test, Nucleai, University of Glasgow Collaboration

    Nov 24 | Diagnostics World | Royal Philips extended their partnership with Cortechs.ai; OCEAN Dx completes a clinical evaluation study for its innovative rapid diagnostic test for sepsis; Nucleai and the University of Glasgow announce a collaboration; and more. More

  • Multiple Biological Dimensions In A Single Assay

    Nov 19 | Diagnostics World | Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment. More

  • Highlights From Last Week’s AMP Meeting

    Nov 18 | Diagnostics World | The Association for Molecular Pathology hosted its 2025 Annual Meeting & Expo last week. Highlights from some of the research presented at the event include faster molecular tests for dangerous regional fungal infections, new Lyme disease tests, AI tools for improving molecular diagnosis, new use for old DNA samples to understand the evolution of colorectal cancer, and more. More

  • Mind the Gap: Whole Genome Sequencing and Phenotype Prediction

    Nov 14 | Diagnostics World | In a study published this week in Nature, researchers from Illumina and The University of Queensland demonstrated the importance of whole-genome sequencing (WGS) to more fully capture the genetics underlying complex human traits and diseases. More

  • Rethinking Diagnosis: Why Clinical Trials Still Misread Women’s Health

    Nov 12 | Diagnostics World | Even though roughly two-thirds of pivotal studies leading to FDA drug approvals now enroll women at rates aligned with their disease burden, their inclusion has “plateaued." Diagnostic criteria and disease models remain largely male-centered because they don’t take into account of the biological and hormonal rhythms that shape women’s health across their lives. That diagnostic blind spot reverberates throughout drug development. More

  • Grail Veterans Launch AI Liquid Biopsy Company

    Nov 11 | Diagnostics World | Veterans of Illumina and Grail launched Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease. Hepta emerged from stealth with $6.7 million in seed funding. More

  • People-Friendly AI Tool Depicts Progression of Osteoarthritis

    Nov 06 | Diagnostics World | For most physicians, concerns about artificial intelligence (AI) continue to outweigh enthusiasm for its potential to improve healthcare decision-making and patient outcomes. Doctors need to understand the reasons behind the predictions of AI tools if they’re expected to use the insights as a starting point for discussing treatment options with their patients. More

  • MeMed Bacterial-Viral Blood Test Trialed in UK

    Nov 04 | Diagnostics World | NHS England is trialing a 15-minute blood test that can distinguish between bacterial or viral infections, identifying serious diseases like sepsis or meningitis quickly in children. The study uses the MeMed BV test. From a small serum or venous whole blood sample, the test measures three host-response biomarkers—TRAIL, IP-10, and CRP. More

  • Nature-Inspired ‘Signaling Cascade’ Enables Drug Monitoring at Home

    Oct 30 | Diagnostics World | When patients are prescribed drugs with a narrow therapeutic window, where the difference between an effective and toxic dose can be frighteningly small, therapeutic drug monitoring is crucial to their safety. Outside of a hospital setting with expensive lab equipment and specialized staff to do the monitoring, things can get dicey. More

  • Pangaea Launches Next-Gen Platform, EpiSign’s METRIC Released, Biodesix, Bio-Rad Laboratories Partner Up

    Oct 29 | Diagnostics World | Pangaea launches its next-generation platform; EpiSign launches its Methylation-based Episignature Testing and Reference-based Interpretation & Classification (METRIC); Biodesix signs an expanded partnership agreement with Bio-Rad Laboratories; and more. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more